The scope of implementation of the basic drug system will be expanded and the Ministry of Health will regulate local supplementation of non-catalogue drugs

The Ministry of Health released the key points of health work in 2012 on February 2 and emphasized that this year will expand the scope of implementation of the national essential medicine system, formulate management measures for the use of essential medicines in medical institutions, and revise the “Guidelines for the clinical application of national essential medicines” and the “National Essential Drug Formulation Set”. 》, Analyze and evaluate the status of basic drug purchases in the previous phase, and study and propose incentives for preferential use of essential drugs.

Two Years of Tackling County Hospital Reform

Financial subsidies become the key

The Ministry of Health stated that this year will promote the implementation of the national essential medicines system in village clinics. For non-governmental grassroots medical and health institutions, it also encourages local governments to adopt procurement services and other methods to gradually incorporate them into the scope of implementation, and through further research, proposes to encourage basic medicines. Priority policies are used to promote the gradual and comprehensive deployment and priority use of essential drugs by other health care institutions. In terms of basic drug procurement, it is necessary to adhere to bulk purchases, linking quantity and price, and integration of recruitment and exploration, focusing on basic drug distribution in rural and remote areas.

In addition, this year, in addition to completing the preparation of the 2012 edition of the National Essential Drugs List for medical and health institutions at all levels, the Ministry of Health stated that it will regulate the local addition of non-catalogue medicines.

In terms of improving the comprehensive evaluation index system for pharmaceutical companies and drug quality, this year, the Ministry of Health will conduct a comprehensive evaluation of clinical use of essential drugs, gradually standardize basic drug dosage forms, specifications and packaging, and continue to enrich and increase monitoring points for essential drug systems, improve monitoring and evaluation. system.

In promoting the pilot reform of public hospitals, the Ministry of Health emphasized that 300 or so counties (cities) with relatively large populations and good foundations will be piloted for the comprehensive reform of county-level hospitals. The reform will break the “medicine-supplementing” mechanism as the key link, reform the compensation mechanism as an entry point, and advance comprehensive reforms such as personnel, preparation, distribution, pricing, payment system, and supervision of county-level hospitals, and at the same time implement the national essential medicine system. Relevant policies have established mechanisms for maintaining public welfare, mobilizing enthusiasm, and ensuring sustainability.

The reporter learned that the pilot scheme for the reform of county-level hospitals has been discussed in the final stage of revision, and will soon be introduced. At present, pilots for reform of county-level hospitals have been launched in Jiangsu, Anhui, and Zhejiang. According to reports, the Ministry of Health plans to promote all county-level hospitals in 2013 after it has opened 300 trials this year. According to statistics, there are currently more than 9,200 county-level hospitals in China, covering nearly one billion people, of which public hospitals account for about 60%, and 300 trials will be rolled out this year, accounting for only 5% of them. This year and next year will become the basic drug system promotion. The year of the storm.

According to the experience of the medical institutions at the primary level, according to the experience of previous trials of township medical institutions, the increase in essential medicines and cheap drugs in primary medical institutions has a greater impact on doctors' income, while financial subsidies are still insufficient, and service charging mechanisms and pricing mechanisms are also in place. It is not perfect, so whether the reform and promotion will be smooth or not in the future depends mainly on the related financial investment in the future, as well as the overall supporting reform of pricing mechanism and subsidy mechanism for medical services.

Cross-regional medical information platform will pilot

Convenient medical treatment

In the area of ​​pharmaceutical supervision, the Ministry of Health stated that it will improve the access mechanism for the clinical application of medical technology, formulate a surgical classification list this year, and focus on strengthening the management of plant (introduction) technical specifications. This year, the "Administrative Measures for Clinical Application of Antimicrobial Agents" and "Administrative Measures for Clinical Pharmacists" will also be formulated to promote the special rectification activities for the clinical application of antibacterial drugs.

The Ministry of Health stated that it will also establish and improve the drug quality traceability system, comprehensively promote the drug electronic regulatory system, and deepen the special rectification of drug safety, carry out medical device standard system (repair) work, and accelerate the construction of medical device standards system.

In support of the development of the Chinese medicine industry, the Ministry of Health stated that it will improve the service system of public Chinese medicine hospitals, increase the clinical application guidelines for essential medicines of Chinese medicine, and take the reform of the compensation mechanism as an entry point to implement the task of comprehensive reform of institutional mechanisms for public hospitals at county level. This year, we will also focus on the promotion of the "Treatise on the Treatment of Diseases" health project to carry out the pilot work on basic public health services for Chinese medicine service projects.

In addition, the Ministry of Health specifically pointed out that China Unicom will pilot some provincial information platforms, promote the construction of regional health information platforms in prefectures and counties, and integrate business application systems based on platform deployment to form a vertical cross-country-province-city-county-township-village landscape. Covers the basic framework of health informatization in major business areas such as public health, medical services, new rural cooperative medical care, pharmaceuticals supply, and comprehensive health management, realizes inter-agency cross-regional interconnection and information sharing within the scope of the pilot, and information on national-level new rural cooperative medical The interconnection between the platform and some provincial-level platforms and medical institutions facilitates farmers who participate in the new rural cooperative medical care to go to other places for medical treatment and report immediately.

Ibrutinib Intermediates

Ibrutinib is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK) that is important in B cells; the drug is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma.
Ibrutinib is used to treat chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, and marginal zone lymphoma.
We produce a series of complete intermediates for Ibrutinib, intermediate I (CAS No. 330786-24-8) and intermediate II (CAS No. 143900-44-1) etc.
All of our products are with stable production and strict quality control, making sure your experience with Sunshine Biotech is always enriching, satisfying and fulfilling.


Pharmaceutical Intermediates

Ibrutinib Intermediates,Cas 330786-24-8,Cas 143900-44-1,High Purity Ibrutinib Intermediates

Nanjing Sunshine Biotech Co., Ltd , https://www.sunshine-bio.com